Midazolam is a widely used central nervous system depressant. It is used for the treatment of insomnia, seizure, and induction of sedation or amnesia for operations. It is metabolized by cytochrome CYP3A and is a widely used probing drug for the evaluation of CYP3A activity in drug-to-drug interaction (DDI) studies. In this study, we develop a method to quantify midazolam in human plasma.

The microbiome continuously shapes its environment through a complex set of interactions, and the microbial flora within and outside the human body has an essential relationship to an organism’s health status. For instance, dysbiosis in the gut microflora is an established contributor to the development of pathological conditions such as chronic inflammatory bowel diseases, type 2 diabetes, and colorectal cancer. In the drug discovery industry, scientists must be proactive in detecting changes in the intestinal microbiome in response to novel therapeutics. Changes to the microbiome associated with probiotic and prebiotic administration must be carefully monitored. Characterizing changes to the gut microbiome whether by metabolic, enzymatic, biomarker, or genomic approaches is fraught with difficulty and has a high assay development and validation cost. Therefore, many companies have looked to partner with research organizations that have success with innovative microbiome analysis tools.

In this webinar, our distinguished speakers, Dr. David Kwok and Dr. David Willoughby discuss current biomarker identification and metabolic evaluation techniques of the human gut microbiome, as well as metagenomic sequencing modalities utilized to streamline results for expedited interpretation and analysis.

Frontage offers full-service radiolabeled human C14 AME (hAME) studies to support your drug development programs.